open access publication

Article, 2024

The economic burden of obesity in 4 south-eastern European countries associated with obesity-related co-morbidities

BMC Health Services Research, ISSN 1472-6963, Volume 24, 1, Page 354, 10.1186/s12913-024-10840-4

Contributors

Athanasakis, Kostas P [1] Bala, Cornelia Gabriela 0000-0001-6216-9088 [2] Kokkinos, Alexander [3] Simonyi, Gábor 0000-0002-5205-3820 [4] Karoliová, Klaudia Hálová [5] Basse, Amaury [6] Bogdanovic, Miodrag (Corresponding author) [7] Kang, Malvin [8] Low, Kaywei [8] Gras, Adrien [8]

Affiliations

  1. [1] University of West Attica
    2. [NORA names: Greece; Europe, EU; OECD];
  2. [2] Iuliu Hațieganu University of Medicine and Pharmacy
    3. [NORA names: Romania; Europe, EU];
  3. [3] National and Kapodistrian University of Athens
    4. [NORA names: Greece; Europe, EU; OECD];
  4. [4] Szent Imre Egyetemi Oktatókórház
    5. [NORA names: Hungary; Europe, EU; OECD];
  5. [5] Institute of Endocrinology
    6. [NORA names: Czechia; Europe, EU; OECD];

Abstract

ObjectiveTo provide an assessment of the cost burden of obesity across a spectrum of obesity-related comorbidities (ORCs) for four countries in South-Eastern Europe (SEE).MethodsA micro-costing analysis from the public payer perspective was conducted to estimate direct healthcare costs associated with ten obesity-related comorbidities (ORCs) in Czech Republic, Greece, Hungary, and Romania. A survey was administered to obtain healthcare resource use and unit cost data. Cost estimates were validated by local steering committees which comprised at least one public sector clinician and a panel of independent industry experts.ResultsChronic kidney disease and cardiovascular diseases were the costliest ORCs across all 4 countries, where annual cost burden per ORC exceeded 1,500 USD per patient per year. In general, costs were driven by the tertiary care resources allocated to address treatment-related adverse events, disease complications, and associated inpatient procedures.ConclusionsOur findings confirm that the high prevalence of obesity and its comorbidities result in substantial financial burden to all 4 SEE public payers. By quantifying the burden of obesity from a public healthcare perspective, our study aims to support policy efforts that promote health education and promotion in combating obesity in the region.

Keywords

Committee, ConclusionsOur, ConclusionsOur findings, Czech, Czech Republic, Europe, Greece, Hungary, MethodsA, Republic, ResultsChronic kidney disease, Romania, South-Eastern Europe, Steering Committee, USD, adverse events, analysis, annual cost burden, assessment, burden, burden of obesity, cardiovascular disease, care resources, clinicians, co-morbidities, comorbidities, complications, cost, cost burden, cost data, cost estimates, countries, data, disease, disease complications, economic burden, economic burden of obesity, education, efforts, estimation, events, experts, findings, health education, healthcare, healthcare costs, healthcare perspective, healthcare resource use, higher prevalence of obesity, highest prevalence, industry, industry experts, inpatient procedures, kidney disease, local steering committee, micro-costing analysis, obesity, obesity-related co-morbidities, obesity-related comorbidities, patients, patients per year, payer perspective, payers, perspective, policy, policy efforts, prevalence of obesity, procedure, promote health education, promoter, public healthcare perspective, public payer perspective, public payers, region, resource use, resources, spectra, study, survey, treatment-related adverse events, unit cost data, units, use, years

Funders

  • Novo Nordisk (Denmark)

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+